The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med - Gilde Healthcare

The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med

April 27, 2021

Investment to support the global expansion of leading manufacturer of precision medical components and devices

Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and contract manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries.

Founded in 1997, Germany-based Acti-Med focuses on tailor-made, highly regulated, cannulas and cannula systems for pharmaceutical and medical applications, jointly developed with international Original Equipment Manufacturers (OEMs). Headquartered in Freiensteinau (Germany) and with operations in Kozerkí (Poland), Acti-Med has attracted clients from all around the world by combining the highest development and engineering capabilities, offering superior quality and operational flexibility. Recent expansions into promising adjacent end markets, supported by innovative best-in-class products highlight the company’s ambitions for growth.

Gilde Healthcare will collaborate with Acti-Med to further strengthen and expand its product portfolio in both the Ready for Market and Ready for Clean room segments, as well as further expand its manufacturing and design capacity to serve its increasing demands from its Pharma and Medical Device customers.

Andreas Schwalb, Founder and CEO of Acti-Med added:

“Acti-Med has had a truly exciting journey over the last 24 years and I am proud to look back on how we have grown our company from scratch into a global leader in our field. I would like to thank everyone at Acti-Med for their invaluable contributions. Now is the right time in our development to bring significant new investment and competencies to support our growth. We are pleased to have attracted Gilde Healthcare, who bring deep sector knowledge and a constructive, collaborative mindset. I look forward to working with Gilde Healthcare for Acti-Med’s successful future.”

Rafael Natanek, Partner at Gilde Healthcare, added:

“We are pleased to complete this acquisition of Acti-Med, a highly regarded contract manufacturer of tailor-made cannula and cannula systems with promising growth opportunities. The company has, through its design-skills, high-quality manufacturing, and flexibility to achieve rapid growth. We are excited to be investing in the company’s continued growth and look forward supporting the management as we consider additional options, such as strategic acquisitions.”

The shareholders of Acti-Med have been advised by DZ BANK Corporate Finance as exclusive M&A advisor.

 

Media contacts:
LifeSci Advisors
Frank Schwarz – fschwarz@lifesciadvisors.com / +49 17 26 15 31 60

Gilde Healthcare
Rafael Natanek – natanek@gildehealthcare.com / +31 61 18 44 63 0

About Acti-Med

Acti-Med is one of the leading manufacturers in the field of medical technology. Headquartered in Freiensteinau, Germany Acti-Med’s competence lies in the development and production of cannulas and cannula systems. Acti-Med develops, produces and sells high-quality medical components and devices for medical and pharmaceutical industries. Our customers are located throughout a wide range of industries, including oncology, pain therapy, the pharmaceutical industry and veterinary medicine. www.acti-med.de.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Private Equity and Venture & Growth. Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022